Recent IP News

University of Minn Waived Its Sovereign Immunity in Inter Partes Review of its Patents

Though this matter does not fall in the medtech or life science areas, it is noteworthy in view of our prior newsletters describing Allergan's attempt at sovereign immunity by transferring its patents to a native tribe. Read more...

Pfizer to Pay $94M to Settle Class Action Over Celebrex Claims

Purchasers of the anti-inflammatory drug Celebrex sued Pfizer claiming that Pfizer abused the patent office process to extend its patent rights to the drug.

Boehringer's Trademark for "Breathless" is Not Merely Descriptive and Can Be Registered

Boehringer sought federal registration of its trademark BREATHLESS for "promoting public awareness of" and "providing medical information about" idiopathic pulmonary fibrosis (IPF)." Read more...

What is an "Extended Release Coating" of a Drug?

Aptalis owned patents to an extended release, skeletal muscle relaxant drug that provided 24 hour relief with a single dose. They sued Apotex for a generic version. Read more...

Click here to be added to the
IP Newsletter mailing list.

WHO WE ARE    Shimokaji IP is an intellectual property law firm. The firm's highly experienced patent attorneys, trademark attorneys and other professionals specialize in patent, trademark, copyright, trade secret, and unfair competition.  

WHAT WE DO    We protect your valuable ideas using our expertise in:

The clients we serve range from start-ups and emerging stage to Fortune 100 companies, and from government entities to universities. From our California office, we easily work with our clients throughout the entire United States and Asia.

HOW WE DO IT    Our commitment is exceptional client service, quality work product, and timeliness – from administrative staff to lawyers.

Michael Shimokaji discusses patents at the UC Irvine Antrepreneur Center